Adaptive Biotechnologies Corp [ADPT] stock is trading at $11.79, down -3.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The ADPT shares have gain 13.58% over the last week, with a monthly amount glided 28.85%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptive Biotechnologies Corp [NASDAQ: ADPT] stock has seen the most recent analyst activity on June 18, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $15. Previously, Goldman upgraded its rating to Buy on March 21, 2025, and kept the price target unchanged to $9. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $15 on January 05, 2023. Piper Sandler upgraded its rating to a Overweight and raised its price target to $14 on December 21, 2022. Credit Suisse started tracking with a Underperform rating for this stock on August 25, 2022, and assigned it a price target of $8. In a note dated June 03, 2022, Piper Sandler initiated an Neutral rating and provided a target price of $7.50 on this stock.
Adaptive Biotechnologies Corp [ADPT] stock has fluctuated between $3.26 and $12.43 over the past year. Currently, Wall Street analysts expect the stock to reach $12.33 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $11.79 at the most recent close of the market. An investor can expect a potential return of 4.58% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
Adaptive Biotechnologies Corp [NASDAQ:ADPT] reported sales of 189.53M for the trailing twelve months, which represents a growth of 25.24%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -0.71%, Pretax Profit Margin comes in at -0.75%, and Net Profit Margin reading is -0.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.66 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.47 points at the first support level, and at 11.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.21, and for the 2nd resistance point, it is at 12.62.
Ratios To Look Out For
For context, Adaptive Biotechnologies Corp’s Current Ratio is 2.92. On the other hand, the Quick Ratio is 2.82, and the Cash Ratio is 0.58. Considering the valuation of this stock, the price to sales ratio is 9.45, the price to book ratio is 9.41.
Transactions by insiders
Recent insider trading involved PISKEL KYLE, Chief Financial Officer, that happened on May 16 ’25 when 1929.0 shares were sold. Chief Scientific Officer, ROBINS HARLAN S completed a deal on May 01 ’25 to sell 68412.0 shares. Meanwhile, Officer Harlan Robins bought 68412.0 shares on May 01 ’25.
